Which has preferable earnings & valuation, MBRX or ATHE?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moleculin Biotech N/A N/A -$33.56M -$17.98 N/A Alterity Therapeutics N/A N/A -$7.87M N/A N/A

Is MBRX or ATHE more profitable?

Company Net Margins Return on Equity Return on Assets Moleculin Biotech N/A N/A -70.93% Alterity Therapeutics N/A N/A N/A

Which has better valuation & earnings, MBRX or PDSB?

PDS Biotechnology is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moleculin Biotech N/A N/A -$33.56M -$17.98 N/A PDS Biotechnology N/A N/A -$34.50M -$0.67 N/A

Is MBRX or PDSB more profitable?

Moleculin Biotech's return on equity of 0.00% beat PDS Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Moleculin Biotech N/A N/A -70.93% PDS Biotechnology N/A -346.02% -102.36%

Is MBRX or HYPD more profitable?

Moleculin Biotech's return on equity of 0.00% beat Hyperion DeFi's return on equity. Company Net Margins Return on Equity Return on Assets Moleculin Biotech N/A N/A -70.93% Hyperion DeFi N/A -91.59% -73.08%

Do analysts prefer MBRX or APLM?

Moleculin Biotech presently has a consensus target price of $22.00, suggesting a potential upside of 937.74%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, equities research analysts plainly believe Moleculin Biotech is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moleculin Biotech 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, MBRX or APLM?

Apollomics has higher revenue and earnings than Moleculin Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moleculin Biotech N/A N/A -$33.56M -$17.98 N/A Apollomics $8.50M 4.80 -$10.94M N/A N/A

Is MBRX or APLM more profitable?

Company Net Margins Return on Equity Return on Assets Moleculin Biotech N/A N/A -70.93% Apollomics N/A N/A N/A

Moleculin Biotech (MBRX) Competitors

$2.12 +0.04 (+1.92%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$2.12 0.00 (-0.24%)

As of 07/24/2026 07:34 PM Eastern

Compare

MBRX vs. BHST, ATHE, PDSB, HYPD, and APLM

Should you buy Moleculin Biotech stock or one of its competitors? MarketBeat compares Moleculin Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Moleculin Biotech include BioHarvest Sciences (BHST), Alterity Therapeutics (ATHE), PDS Biotechnology (PDSB), Hyperion DeFi (HYPD), and Apollomics (APLM). These companies are all part of the "pharmaceutical products" industry.

How does Moleculin Biotech compare to BioHarvest Sciences?

BioHarvest Sciences (NASDAQ:BHST) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

BioHarvest Sciences presently has a consensus target price of $10.00, indicating a potential upside of 420.83%. Moleculin Biotech has a consensus target price of $22.00, indicating a potential upside of 937.74%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than BioHarvest Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioHarvest Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Moleculin Biotech has a net margin of 0.00% compared to BioHarvest Sciences' net margin of -32.54%. Moleculin Biotech's return on equity of 0.00% beat BioHarvest Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioHarvest Sciences	-32.54%	-76.03%	-25.30%
Moleculin Biotech	N/A	N/A	-70.93%

15.5% of Moleculin Biotech shares are held by institutional investors. 1.1% of Moleculin Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

BioHarvest Sciences has higher revenue and earnings than Moleculin Biotech. BioHarvest Sciences is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioHarvest Sciences	$35.16M	1.07	-$11.14M	-$0.59	N/A
Moleculin Biotech	N/A	N/A	-$33.56M	-$17.98	N/A

BioHarvest Sciences has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market. Comparatively, Moleculin Biotech has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market.

In the previous week, BioHarvest Sciences and BioHarvest Sciences both had 1 articles in the media. Moleculin Biotech's average media sentiment score of 1.28 beat BioHarvest Sciences' score of 1.23 indicating that Moleculin Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
BioHarvest Sciences	Positive
Moleculin Biotech	Positive

Summary

Moleculin Biotech beats BioHarvest Sciences on 10 of the 14 factors compared between the two stocks.

How does Moleculin Biotech compare to Alterity Therapeutics?

Moleculin Biotech (NASDAQ:MBRX) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

In the previous week, Alterity Therapeutics had 1 more articles in the media than Moleculin Biotech. MarketBeat recorded 2 mentions for Alterity Therapeutics and 1 mentions for Moleculin Biotech. Moleculin Biotech's average media sentiment score of 1.28 beat Alterity Therapeutics' score of 0.62 indicating that Moleculin Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Moleculin Biotech	Positive
Alterity Therapeutics	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moleculin Biotech	N/A	N/A	-$33.56M	-$17.98	N/A
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A

Moleculin Biotech presently has a consensus price target of $22.00, suggesting a potential upside of 937.74%. Alterity Therapeutics has a consensus price target of $13.00, suggesting a potential upside of 186.34%. Given Moleculin Biotech's higher probable upside, research analysts plainly believe Moleculin Biotech is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

15.5% of Moleculin Biotech shares are owned by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are owned by institutional investors. 1.1% of Moleculin Biotech shares are owned by insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Moleculin Biotech has a beta of 1.75, suggesting that its stock price is 75% more volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Moleculin Biotech	N/A	N/A	-70.93%
Alterity Therapeutics	N/A	N/A	N/A

Summary

Alterity Therapeutics beats Moleculin Biotech on 6 of the 10 factors compared between the two stocks.

How does Moleculin Biotech compare to PDS Biotechnology?

Moleculin Biotech (NASDAQ:MBRX) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

15.5% of Moleculin Biotech shares are owned by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are owned by institutional investors. 1.1% of Moleculin Biotech shares are owned by company insiders. Comparatively, 8.4% of PDS Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Moleculin Biotech currently has a consensus target price of $22.00, suggesting a potential upside of 937.74%. PDS Biotechnology has a consensus target price of $9.00, suggesting a potential upside of 1,220.81%. Given PDS Biotechnology's higher probable upside, analysts plainly believe PDS Biotechnology is more favorable than Moleculin Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Moleculin Biotech's return on equity of 0.00% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moleculin Biotech	N/A	N/A	-70.93%
PDS Biotechnology	N/A	-346.02%	-102.36%

Moleculin Biotech has a beta of 1.75, suggesting that its stock price is 75% more volatile than the broader market. Comparatively, PDS Biotechnology has a beta of 1.59, suggesting that its stock price is 59% more volatile than the broader market.

In the previous week, PDS Biotechnology had 1 more articles in the media than Moleculin Biotech. MarketBeat recorded 2 mentions for PDS Biotechnology and 1 mentions for Moleculin Biotech. Moleculin Biotech's average media sentiment score of 1.28 beat PDS Biotechnology's score of 0.77 indicating that Moleculin Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Moleculin Biotech	Positive
PDS Biotechnology	Positive

PDS Biotechnology is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moleculin Biotech	N/A	N/A	-$33.56M	-$17.98	N/A
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A

Summary

Moleculin Biotech beats PDS Biotechnology on 6 of the 11 factors compared between the two stocks.

How does Moleculin Biotech compare to Hyperion DeFi?

Moleculin Biotech (NASDAQ:MBRX) and Hyperion DeFi (NASDAQ:HYPD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

Moleculin Biotech presently has a consensus target price of $22.00, indicating a potential upside of 937.74%. Hyperion DeFi has a consensus target price of $6.95, indicating a potential upside of 176.89%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, equities analysts plainly believe Moleculin Biotech is more favorable than Hyperion DeFi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Hyperion DeFi	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Moleculin Biotech's return on equity of 0.00% beat Hyperion DeFi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moleculin Biotech	N/A	N/A	-70.93%
Hyperion DeFi	N/A	-91.59%	-73.08%

Moleculin Biotech has higher earnings, but lower revenue than Hyperion DeFi. Hyperion DeFi is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moleculin Biotech	N/A	N/A	-$33.56M	-$17.98	N/A
Hyperion DeFi	$1.04M	36.48	-$45.31M	-$9.95	N/A

In the previous week, Moleculin Biotech and Moleculin Biotech both had 1 articles in the media. Hyperion DeFi's average media sentiment score of 1.87 beat Moleculin Biotech's score of 1.28 indicating that Hyperion DeFi is being referred to more favorably in the news media.

Company	Overall Sentiment
Moleculin Biotech	Positive
Hyperion DeFi	Very Positive

Moleculin Biotech has a beta of 1.75, indicating that its share price is 75% more volatile than the broader market. Comparatively, Hyperion DeFi has a beta of 2.49, indicating that its share price is 149% more volatile than the broader market.

15.5% of Moleculin Biotech shares are held by institutional investors. Comparatively, 25.8% of Hyperion DeFi shares are held by institutional investors. 1.1% of Moleculin Biotech shares are held by insiders. Comparatively, 7.5% of Hyperion DeFi shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Moleculin Biotech and Hyperion DeFi tied by winning 6 of the 12 factors compared between the two stocks.

How does Moleculin Biotech compare to Apollomics?

Moleculin Biotech (NASDAQ:MBRX) and Apollomics (NASDAQ:APLM) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

Moleculin Biotech has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market. Comparatively, Apollomics has a beta of 1.44, meaning that its share price is 44% more volatile than the broader market.

In the previous week, Moleculin Biotech and Moleculin Biotech both had 1 articles in the media. Moleculin Biotech's average media sentiment score of 1.28 beat Apollomics' score of 0.93 indicating that Moleculin Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Moleculin Biotech	Positive
Apollomics	Positive

Moleculin Biotech presently has a consensus target price of $22.00, suggesting a potential upside of 937.74%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, equities research analysts plainly believe Moleculin Biotech is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Apollomics has higher revenue and earnings than Moleculin Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moleculin Biotech	N/A	N/A	-$33.56M	-$17.98	N/A
Apollomics	$8.50M	4.80	-$10.94M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Moleculin Biotech	N/A	N/A	-70.93%
Apollomics	N/A	N/A	N/A

15.5% of Moleculin Biotech shares are owned by institutional investors. Comparatively, 19.1% of Apollomics shares are owned by institutional investors. 1.1% of Moleculin Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Moleculin Biotech beats Apollomics on 6 of the 10 factors compared between the two stocks.

Get Moleculin Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MBRX vs. The Competition

Export

Metric	Moleculin Biotech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$11.10M	$3.67B	$6.87B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-0.12	21.48	27.14	23.64
Price / Sales	N/A	170.08	517.06	88.99
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	0.45	7.88	10.28	6.07
Net Income	-$33.56M	$23.86M	$3.60B	$331.99M
7 Day Performance	0.95%	-3.82%	-1.27%	-0.63%
1 Month Performance	-29.10%	-2.61%	-0.37%	-2.00%
1 Year Performance	-85.04%	32.79%	18.30%	13.62%

Moleculin Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MBRX Moleculin Biotech	3.1222 of 5 stars	$2.12 +1.9%	$22.00 +937.7%	-86.7%	$11.10M	N/A	N/A	20	Positive News
BHST BioHarvest Sciences	3.0204 of 5 stars	$2.18 -4.4%	$10.00 +358.7%	-75.5%	$44.72M	$34.51M	N/A	N/A	Positive News Gap Up High Trading Volume
ATHE Alterity Therapeutics	3.2783 of 5 stars	$4.70 -5.6%	$13.00 +176.6%	-20.1%	$44.16M	N/A	N/A	10	Gap Down
PDSB PDS Biotechnology	2.4308 of 5 stars	$0.72 -5.9%	$9.00 +1,157.9%	-43.7%	$42.50M	N/A	N/A	20	News Coverage Positive News Analyst Downgrade
HYPD Hyperion DeFi	3.17 of 5 stars	$2.76 flat	$6.95 +151.8%	-69.3%	$41.83M	$810K	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MBRX) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Moleculin Biotech (MBRX) Competitors

MBRX vs. BHST, ATHE, PDSB, HYPD, and APLM

How does Moleculin Biotech compare to BioHarvest Sciences?

Summary

How does Moleculin Biotech compare to Alterity Therapeutics?

Summary

How does Moleculin Biotech compare to PDS Biotechnology?

Summary

How does Moleculin Biotech compare to Hyperion DeFi?

Summary

How does Moleculin Biotech compare to Apollomics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBRX vs. The Competition

Moleculin Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Moleculin Biotech (MBRX) Competitors

MBRX vs. BHST, ATHE, PDSB, HYPD, and APLM

How does Moleculin Biotech compare to BioHarvest Sciences?

Do analysts rate BHST or MBRX?

Is BHST or MBRX more profitable?

Do insiders and institutionals believe in BHST or MBRX?

Which has preferable earnings & valuation, BHST or MBRX?

Which has more volatility and risk, BHST or MBRX?

Does the media prefer BHST or MBRX?

Summary

How does Moleculin Biotech compare to Alterity Therapeutics?

Does the media prefer MBRX or ATHE?

Which has preferable earnings & valuation, MBRX or ATHE?

Do analysts prefer MBRX or ATHE?

Do institutionals & insiders hold more shares of MBRX or ATHE?

Which has more volatility and risk, MBRX or ATHE?

Is MBRX or ATHE more profitable?

Summary

How does Moleculin Biotech compare to PDS Biotechnology?

Do insiders & institutionals hold more shares of MBRX or PDSB?

Do analysts recommend MBRX or PDSB?

Is MBRX or PDSB more profitable?

Which has more volatility & risk, MBRX or PDSB?

Does the media prefer MBRX or PDSB?

Which has better valuation & earnings, MBRX or PDSB?

Summary

How does Moleculin Biotech compare to Hyperion DeFi?

Do analysts rate MBRX or HYPD?

Is MBRX or HYPD more profitable?

Which has better valuation and earnings, MBRX or HYPD?

Does the media favor MBRX or HYPD?

Which has more risk and volatility, MBRX or HYPD?

Do institutionals & insiders believe in MBRX or HYPD?

Summary

How does Moleculin Biotech compare to Apollomics?

Which has more volatility and risk, MBRX or APLM?

Does the media refer more to MBRX or APLM?

Do analysts prefer MBRX or APLM?

Which has better valuation and earnings, MBRX or APLM?

Is MBRX or APLM more profitable?

Do institutionals & insiders hold more shares of MBRX or APLM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBRX vs. The Competition

Moleculin Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools